A-Alpha Bio provides cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio's product, AlphaSeq, is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck.

Altos Labs is a new biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine.

Biofidelity developed a revolutionary molecular diagnostic assay that enables the rapid detection of target DNA sequences. Biofidelity’s mission is to improve and extend patients’ lives by enabling early detection of disease and better targeting of treatments with applications spanning oncology, prenatal testing, infectious disease, and organ transplant monitoring. Biofidelity was founded in 2019 and is headquartered of Cambridge, England.

Bruker Corporation is a provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.

CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies. CARGO is on a mission to outsmart cancer by advancing a new generation of best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. In addition, far too many patients are unable to access these potentially curative therapies due to other challenges, including manufacturing, supply constraints, slow turnaround time and reimbursement hurdles. The team at CARGO is intensely focused on pursuing novel solutions to achieve better cancer treatment outcomes and experiences.

Elucidata's mission is to use data analytics to transform decision-making processes in R&D labs in biotechnology and pharmaceutical companies. We build algorithms and software to process, analyze and visualize large omics data across metabolomics, genomics, transcriptomics, and proteomics among others. We build our own products, provide customized solutions for our partners, and analyze datasets to answer specific questions.

At Enable Medicine, we are mapping biology to guide better drug development and the future of patient care. We are a venture backed, biotechnology company that leverages spatial biology data and AI-driven analyses to provide new insights into disease. Our platform allows researchers, pharmaceutical companies and clinicians to generate and search biologic maps for answers they need. Our lab currently provides end-to-end services including data acquisition, utilizing powerful multiplex imaging systems, to data analysis with our proprietary software tools. These systems allows for the measurement of 40+ biomarkers at cellular resolution on a single tissue section. With our partners, we have investigated indications ranging from cancer to neurodegenerative disorders. It is our goal to provide our clients with best-in-class spatial biology data acquisition, and to enable them with software tools to bridge the gap between data and clinical insights.

At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies. We are pioneers who rapidly translate discoveries into innovations and innovations into differentiated therapeutic solutions, to address the most significant unmet medical needs in oncology.

We make genomics affordable and accessible through a cost-effective low-coverage whole genome sequencing technology

Haystack Oncology applies the next-generation of ctDNA detection technology to deliver industry-leading sensitivity and specificity for transformative MRD testing

Nodexus is a Venture Capital-backed, UC Berkeley/Stanford StartX biotech company commercializing technology solutions to make cutting-edge single-cell workflows in gene editing, cancer biology, agriculture, and more universally accessible.

At Paragon Genomics, we develop and commercialize rapid, easy-to-use, ultra-high multiplex PCR-based target enrichment solutions for Next-Generation Sequencing (NGS). Our proprietary CleanPlex® background-removing technology enables NGS customers to develop targeted sequencing assays that are accurate, sensitive, and simple, yet cost effective. Our technology is applicable to many fast-growing NGS segments such as cancer research, liquid biopsy, biomarker discovery, genomics-guided breeding, companion diagnostics, and immunotherapy monitoring.